Quarterly report pursuant to Section 13 or 15(d)

ASSET ACQUISITION (Details)

v3.23.1
ASSET ACQUISITION (Details)
$ in Millions
 1 Months Ended 3 Months Ended
Jan. 31, 2022
USD ($)
item
Mar. 31, 2023
item
Jan. 12, 2022
USD ($)
Asset Acquisition      
Number of branded drugs in product portfolio | item 8 8  
Vyne product acquisition      
Asset Acquisition      
Upfront payment $ 20.0    
Additional payment     $ 5.0
One-time payment $ 450.0    
Percentage of upfront payment received 10.00%    
Vyne product acquisition | If annual sales reaches to $100 million      
Asset Acquisition      
Annual sales $ 100.0    
One-time payment 10.0    
Vyne product acquisition | If annual sales reaches to $200 million      
Asset Acquisition      
Annual sales 200.0    
One-time payment 20.0    
Vyne product acquisition | If annual sales reaches to $300 million      
Asset Acquisition      
Annual sales 300.0    
One-time payment 30.0    
Vyne product acquisition | If annual sales reaches to $400 million      
Asset Acquisition      
Annual sales 400.0    
One-time payment 40.0    
Vyne product acquisition | If annual sales reaches to $500 million      
Asset Acquisition      
Annual sales 500.0    
One-time payment $ 50.0    
Minocycline products      
Asset Acquisition      
Business Acquisition interest 4.00%    
Molecule Stabilizing Technology      
Asset Acquisition      
Business Acquisition interest 1.50%